DE10393824D2 - Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze - Google Patents

Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze

Info

Publication number
DE10393824D2
DE10393824D2 DE10393824T DE10393824T DE10393824D2 DE 10393824 D2 DE10393824 D2 DE 10393824D2 DE 10393824 T DE10393824 T DE 10393824T DE 10393824 T DE10393824 T DE 10393824T DE 10393824 D2 DE10393824 D2 DE 10393824D2
Authority
DE
Germany
Prior art keywords
oncoviruses
leukemia virus
vaccine against
feline leukemia
against infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE10393824T
Other languages
German (de)
English (en)
Inventor
Claas Junghans
Matthias Schroff
Christiane Juhls
Detlef Oswald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mologen AG
Original Assignee
Mologen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologen AG filed Critical Mologen AG
Priority to DE10393824T priority Critical patent/DE10393824D2/de
Application granted granted Critical
Publication of DE10393824D2 publication Critical patent/DE10393824D2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE10393824T 2002-09-23 2003-09-19 Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze Expired - Fee Related DE10393824D2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE10393824T DE10393824D2 (de) 2002-09-23 2003-09-19 Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10244863 2002-09-23
PCT/DE2003/003179 WO2004028562A2 (de) 2002-09-23 2003-09-19 Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
DE10393824T DE10393824D2 (de) 2002-09-23 2003-09-19 Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze

Publications (1)

Publication Number Publication Date
DE10393824D2 true DE10393824D2 (de) 2005-08-11

Family

ID=32038184

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10393824T Expired - Fee Related DE10393824D2 (de) 2002-09-23 2003-09-19 Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze
DE50304603T Expired - Lifetime DE50304603D1 (de) 2002-09-23 2003-09-19 Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50304603T Expired - Lifetime DE50304603D1 (de) 2002-09-23 2003-09-19 Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze

Country Status (9)

Country Link
US (1) US7915035B2 (https=)
EP (1) EP1553977B1 (https=)
JP (1) JP4411213B2 (https=)
AT (1) ATE335507T1 (https=)
AU (1) AU2003281917A1 (https=)
DE (2) DE10393824D2 (https=)
DK (1) DK1553977T3 (https=)
ES (1) ES2270120T3 (https=)
WO (1) WO2004028562A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0901593D0 (en) * 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
US8895027B2 (en) * 2011-07-20 2014-11-25 Merial Limited Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
JP7731670B2 (ja) * 2017-11-06 2025-09-01 インターベット インターナショナル ベー． フェー． ネコ白血病ウイルスワクチン
EP3706789A1 (en) 2017-11-06 2020-09-16 Intervet International B.V. Feline calicivirus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
US6696291B2 (en) * 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
SE9803099D0 (sv) * 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
ES2242888T3 (es) * 2001-10-02 2005-11-16 Mologen Ag Constructo de expresion de adn para el tratamiento de infecciones por leishmaniosis.

Also Published As

Publication number Publication date
EP1553977B1 (de) 2006-08-09
WO2004028562A3 (de) 2004-06-03
JP2006511211A (ja) 2006-04-06
EP1553977A2 (de) 2005-07-20
DE50304603D1 (de) 2006-09-21
AU2003281917A1 (en) 2004-04-19
US7915035B2 (en) 2011-03-29
AU2003281917A8 (en) 2004-04-19
US20060240034A1 (en) 2006-10-26
JP4411213B2 (ja) 2010-02-10
DK1553977T3 (da) 2006-11-27
ATE335507T1 (de) 2006-09-15
WO2004028562A2 (de) 2004-04-08
ES2270120T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
AR032231A1 (es) Nuevas proteinas insecticidas de bacillus thuringiensis
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
ATE462003T1 (de) Aus wt1 stammende krebsantigenpeptide
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
BR0212684B1 (pt) seringa retrátil de utilização única.
EA200700904A1 (ru) Вакцины против вируса японского энцефалита и вируса западного нила
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
NO20052149D0 (no) Vaksine.
DE10393824D2 (de) Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze
ATE294857T1 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
ATE380557T1 (de) E. coli vakzin zur protektion von geflügel gegen colibazillose
WO2004071462A3 (en) Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction
DK1196607T3 (da) Antibakterielt chlamysin B-protein, gen kodende derfor samt ekspressionssystem
ATE476197T1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
CY1105629T1 (el) Πολυπεπτιδιο που επαγει αντισωματα εξουδετερωσης του ηιv
ATE414905T1 (de) Diabetesmodell
WO2005003325A3 (en) Inhibition of viral pathogenesis
CY1107371T1 (el) Αυξηση της θυμοσινης στην γενετικη ανοσοποιηση
WO2004027066A3 (fr) Protéine recombinante chimérique et diagnostic in vitro du hiv
AU2003240866A1 (en) Antibodies, peptides and vaccines against hiv-1 virus
WO2004101607A3 (en) Comparative ligand mapping from mhc class i positive cells
DK1418941T3 (da) Induktion af immunrespons mod felint immundefektvirus
TW200621800A (en) Human immunodeficiency virus vaccine
WO2005010163A3 (en) Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
ATE506439T1 (de) Codon-optimisierte hiv-rt-nef-gag dna impfstoffe

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee